Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations
Substance Use and Addiction Journal
This is a narrative review of methadone and buprenorphine regulations, prescriber eligibility, dispensing models, and coverage across eight countries: the United States, Canada, the United Kingdom, Russia, France, Iran, Australia, and Portugal. The study identified several key barriers to MOUD: requirements for daily supervised dosing, restricted community prescribing, and stigmatizing drug scheduling. The authors highlight policies that improved MOUD access without compromising safety such as: 1) community pharmacy dispensing supports in the U.K. and Australia, 2) liberal buprenorphine prescribing in primary care in France, and 3) decriminalization and expansion of low-threshold public health models in Portugal and Iran.
 
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

This Week in Addiction Medicine from ASAM

American Society of Addiction Medicine

Lead: Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations

DEC 9, 20255 MIN
This Week in Addiction Medicine from ASAM

Lead: Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations

DEC 9, 20255 MIN

Description

Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations Substance Use and Addiction Journal This is a narrative review of methadone and buprenorphine regulations, prescriber eligibility, dispensing models, and coverage across eight countries: the United States, Canada, the United Kingdom, Russia, France, Iran, Australia, and Portugal. The study identified several key barriers to MOUD: requirements for daily supervised dosing, restricted community prescribing, and stigmatizing drug scheduling. The authors highlight policies that improved MOUD access without compromising safety such as: 1) community pharmacy dispensing supports in the U.K. and Australia, 2) liberal buprenorphine prescribing in primary care in France, and 3) decriminalization and expansion of low-threshold public health models in Portugal and Iran.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM